Optimizing the science of drug development: opportunities for better candidate selection and accelerated evaluation in humans.

Pharm Res

Office of Clinical Pharmacology and Biopharmaceutics, Center for Drug Evaluation and Research, Food and Drug Administration, Rockville, Maryland 20851, USA.

Published: November 2000

Download full-text PDF

Source
http://dx.doi.org/10.1023/a:1007574217260DOI Listing

Publication Analysis

Top Keywords

optimizing science
4
science drug
4
drug development
4
development opportunities
4
opportunities better
4
better candidate
4
candidate selection
4
selection accelerated
4
accelerated evaluation
4
evaluation humans
4

Similar Publications

Background: To investigate the trends in Burkitt lymphoma incidence, mortality, and disability-adjusted life-years, considering sex and age, from 1990 to 2021, with a 20-year forecast.

Method: Data regarding Burkitt lymphoma were extracted from the Global Burden of Disease study for the year 2021.

Results: Globally, there were 19,072 incident cases of Burkitt lymphoma in 2021.

View Article and Find Full Text PDF

Dynamic-budget superpixel active learning for semantic segmentation.

Front Artif Intell

January 2025

Department of Computer Science, University of Saskatchewan, Saskatoon, SK, Canada.

Introduction: Active learning can significantly decrease the labeling cost of deep learning workflows by prioritizing the limited labeling budget to high-impact data points that have the highest positive impact on model accuracy. Active learning is especially useful for semantic segmentation tasks where we can selectively label only a few high-impact regions within these high-impact images. Most established regional active learning algorithms deploy a static-budget querying strategy where a fixed percentage of regions are queried in each image.

View Article and Find Full Text PDF

Background: Large language models (LLMs) have demonstrated impressive performance on medical licensing and diagnosis-related exams. However, comparative evaluations to optimize LLM performance and ability in the domain of comprehensive medication management (CMM) are lacking. The purpose of this evaluation was to test various LLMs performance optimization strategies and performance on critical care pharmacotherapy questions used in the assessment of Doctor of Pharmacy students.

View Article and Find Full Text PDF

Background: The differential diagnosis between benign and malignant thyroid nodules continues to be a major challenge in clinical practice. The rising incidence of thyroid neoplasm and the low incidence of aggressive thyroid carcinoma, urges the exploration of strategies to improve the diagnostic accuracy in a pre-surgical phase, particularly for indeterminate nodules, and to prevent unnecessary surgeries. Only in 2022, the 5th WHO Classification of Endocrine and Neuroendocrine Tumors, and in 2023, the 3rd Bethesda System for Reporting Thyroid Cytopathology and the European Thyroid Association included biomarkers in their guidelines.

View Article and Find Full Text PDF

Background: Antibody-drug conjugate (ADC) is an anticancer drug that links toxins to specifically targeted antibodies via linkers, offering the advantages of high target specificity and high cytotoxicity. However, complexity of its structural composition poses a greater difficulty for drug design studies.

Objectives: Pharmacokinetic/pharmacodynamic (PK/PD) based consideration of ADCs has increasingly become a hot research topic for optimal drug design in recent years, providing possible ideas for obtaining ADCs with desirable properties.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!